Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), has completed its $16.5 billion, all-cash acquisition of contract development and manufacturing firm Catalent (CLCT), the companies said on Wednesday.
Under terms of the transaction, Catalent shareholders received $63.50 in cash for each of their share, a premium of around 47.5% to the volume-weighted average price of the stock prior to the deal being announced in early February.
Catalent shares stopped trading on Wednesday and are being delisted from the New York Stock Exchange, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments